Clinical Trials Directory

Trials / Completed

CompletedNCT02858128

WB-DW-MRI vs CHOLINE-PET/CT for Selecting Treatments in Recurrent Prostate Cancer

WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (WB-DW-MRI) VS CHOLINE-POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (CHOLINE- PET/CT) for Selecting Treatments in Recurrent Prostate Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
46 (actual)
Sponsor
Hospital Provincial de Castellon · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW- MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with metastatic/oligometastatic prostate cancer. Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated.

Detailed description

This was a prospective, controlled, unicentric study, involving 46 consecutive patients from our centre who presented biochemical relapse after adjuvant, salvage or radical treatment with external beam radiotherapy, or brachytherapy. After initial tests ( bone scintigraphy, CT, pelvic MRI) 35 patients with oligometastases or without them were selected. 11 patients with multiple metastases were excluded from the study. WB-DW- MRI and choline-PET/CT was then performed on each patient within one week. The results were interpreted by specialists in nuclear medicine and MRI. If they were candidates for treatment with ablative SBRT (SABR) they were then evaluated every three months with both tests.

Conditions

Interventions

TypeNameDescription
OTHERIMAGING STUDYCholine-PET/CT versus NMRscan comparative study

Timeline

Start date
2014-10-01
Primary completion
2015-03-01
Completion
2015-03-01
First posted
2016-08-08
Last updated
2016-08-09

Source: ClinicalTrials.gov record NCT02858128. Inclusion in this directory is not an endorsement.